Advertisement

Nootrop wirkende Substanzen

  • M. Schmitz

Zusammenfassung

Die Alzheimer-Krankheit ist die häufigste geriatrische Krankheit. 5% der über 65jährigen leiden daran. Diese Zahl steigt rapide mit dem Lebensalter an, und bei den über 8ojährigen sind es schon über 10 bis 20%. Allerdings kann die Krankheit schon bei 35jährigen beginnen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Psychiatric Association (1995) 148th Annual Meeting. Topic 8: Organic Mental Disorders Bloom FE, Kupfer DJ (Hrsg.) (1995) Psychopharmacology. The Fourth Generation in Progress; Geriatric Disorders: 1361–1479; Raven, NYGoogle Scholar
  2. Pierpaoli W, Regelson W, Fabris N (Hrsg.) (1994) The Aging Clock; Ann NY Acad Sci 719 Clark R, Goate A (1993) Molecular genetics of Alzheimer’s disease. Arch Neurol 50: 1164–1172Google Scholar
  3. Cohen RM, Weingartner HW, Smallberg A, Pickar D, Murphy DL (1982) Effort and cognition in depression. Arch Gen Psychiatry 39: 593–597Google Scholar
  4. Davis KL, Thal LJ, Gamzu E et al. (1992) Tacrine in patients with Alzheimer’s disease: a double blind placebo controlled multicenter study. N Engl J Med 327: 374–1379Google Scholar
  5. Mohs RC (1991) Assessment of cognitive symptoms in clinical studies of antidementia drugs (Homma A. trans): Jpn J Geriatr Psychiatry 2: 1195–1201Google Scholar
  6. Rapoport SI, Grady CL (1993) Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer disease. J Neurosci 7o: 39–56Google Scholar
  7. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (199o) Evidence that 13-amyloid protein in Alzheimer’s disease is not derived by normal processing. Science 248: 492–495Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. Schmitz

There are no affiliations available

Personalised recommendations